<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03987620</url>
  </required_header>
  <id_info>
    <org_study_id>SCY-078-306</org_study_id>
    <nct_id>NCT03987620</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis</brief_title>
  <acronym>Vanish 306</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (AVVC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scynexis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Scynexis, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to
      evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in
      female subjects 12 years and older with AVVC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who meet all of the inclusion and none of the exclusion criteria will be enrolled
      into the study and will be randomized in a 2:1 ratio to either oral ibrexafungerp or
      ibrexafungerp matching placebo, as follows:

        -  Oral ibrexafungerp 300-mg dose BID (bis in die) for 1 day

        -  Oral ibrexafungerp matching placebo BID for 1 day

      This is a randomized, double-blind study.

      Approximately 366 eligible subjects will be enrolled and randomized in a 2:1 ratio to one of
      the two study treatment groups. Subjects will be followed for assessments of efficacy and
      safety for approximately one month after study drug administration. The design of this study
      is identical to VANISH 303 Study: NCT03734991
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 7, 2019</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled, double-blind study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure (complete resolution of signs and symptoms)</measure>
    <time_frame>Day 8-14</time_frame>
    <description>The percentage of subjects with clinical cure (complete resolution of signs and symptoms) at the test-of-cure (TOC) visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mycological eradication (negative culture for growth of yeast)</measure>
    <time_frame>Day 8-14</time_frame>
    <description>The percentage of subjects with mycological eradication (negative culture for growth of Candida species) at the TOC visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical cure and mycological eradication (responder outcome)</measure>
    <time_frame>Day 8-14</time_frame>
    <description>The percentage of subjects with clinical cure and mycological eradication (responder outcome) at the TOC visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete resolution of signs and symptoms at follow-up</measure>
    <time_frame>Day 25</time_frame>
    <description>The percentage of subjects with complete resolution of symptoms at the Follow-up (FU) visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of Ibrexafungerp</measure>
    <time_frame>Up to 29 Days</time_frame>
    <description>Number of subjects with treatment related adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Candida Vulvovaginitis</condition>
  <arm_group>
    <arm_group_label>Ibrexafungerp (SCY-078)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg BID for one day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrexafungerp</intervention_name>
    <description>Ibrexafungerp 300mg BID for one day</description>
    <arm_group_label>Ibrexafungerp (SCY-078)</arm_group_label>
    <other_name>SCY-078</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a postmenarchal female subject 12 years and older

          -  Subject has a diagnosis of symptomatic AVVC at baseline including a positive
             microscopic examination with 10% Potassium Hydroxide (KOH) in a vaginal sample
             revealing yeast forms (hyphae/pseudohyphae) or budding yeasts, and vaginal pH (â‰¤4.5)

        Exclusion Criteria:

          -  Subject has any vaginal condition other than AVVC that may interfere with the
             diagnosis or evaluation of response to therapy, such as suspected or confirmed
             concurrent causes of vulvovaginitis and/or cervicitis (mixed infection)

          -  Need for systemic and/or topical (vaginal) anti fungal treatment, including
             prescription or over-the-counter products during the study and treatment for
             vulvovaginal candidiasis (VVC) 28 days prior to randomization.

          -  Subject has uncontrolled diabetes mellitus.

          -  Subject has a vaginal sample with pH &gt;4.5.

          -  Subject has a history of or an active cervical/vaginal cancer.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mesa OB-GYN</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Red Rocks OBGYN</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood Southern New England</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Generation Medical Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Clinical Data Inc</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician Care Clinical Research LLC</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCT LLC - A VitaLink Company- PPDS</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Clinical Research, LLC</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fellows Research Alliance Inc</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosemark Women Care Specialists</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praetorian Pharmaceutical Research, LLC</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North County Health Center, Planned Parenthood of the St. Louis Region and Southwest Missouri</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center Of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood North Central Southern New Jersey (PPNCSNJ)</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Institute for Clinical Research - M3 Wake Research</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obstetrics and Gynecology Associates of Erie, PC</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood Southeastern Pennsylvania The Elizabeth Blackwell Health Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fellows Research Alliance Inc</name>
      <address>
        <city>Bluffton</city>
        <state>South Carolina</state>
        <zip>29910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Medical Research Inc</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signature GYN Services, PLLC</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brownstone Clinical Trials, LLC</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment -Asenovgrad EOOD</name>
      <address>
        <city>Asenovgrad</city>
        <zip>4230</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Puls AD - PPDS</name>
      <address>
        <city>Blagoevgrad</city>
        <zip>2700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Chirpan EOOD</name>
      <address>
        <city>Chirpan</city>
        <zip>6200</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Asklepii OOD</name>
      <address>
        <city>Dupnitsa</city>
        <zip>2600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic-Consultative Center I-Gabrovo EOOD</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital For Active Treatment Dr Tota Venkova</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Sv. Ivan Rilski - Gorna Oryahovitsa EOOD</name>
      <address>
        <city>Gorna Oryahovitsa</city>
        <zip>5100</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment- Sveti Nikolay Chudotvoretz - LOM EOOD</name>
      <address>
        <city>Lom</city>
        <zip>3600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Prof. Dr. Paraskev Stoyanov AD</name>
      <address>
        <city>Lovech</city>
        <zip>5500</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Stamen Iliev AD</name>
      <address>
        <city>Montana</city>
        <zip>3400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital For Active Treatment - Pazardzhik AD</name>
      <address>
        <city>Pazardzhik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Trimontsium OOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Samokov EOOD</name>
      <address>
        <city>Samokov</city>
        <zip>2000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center-1-Sevlievo EOOD</name>
      <address>
        <city>Sevlievo</city>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Shumen</name>
      <address>
        <city>Shumen</city>
        <zip>9700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital For Active Treatment - Dr. Bratan Shukerov AD</name>
      <address>
        <city>Smolyan</city>
        <zip>4700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Excelsior OOD - PPDS</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consultative CTR - XX - Sofia - EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1618</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical center Vip Clinic OOD</name>
      <address>
        <city>Sofia</city>
        <zip>1680</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Medica Plus OOD</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>June 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaginitis</keyword>
  <keyword>Yeast infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
    <mesh_term>Vulvovaginitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

